ArticleFrontiers in cellular and infection microbiology2026
Interpretable machine learning identifies a clinically inferred inflammasome-associated inflammatory injury phenotype in children with adenovirus pneumonia.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe adenovirus pneumonia in children is characterized by persistent fever, systemic inflammation, and extrapulmonary tissue injury. Although adenovirus can activate inflammasome pathways, direct inflammasome biomarkers are not routinely available in pediatric practice. This study developed an interpretable machine-learning framework for retrospective severity discrimination and inflammatory phenotype stratification. Methods: We retrospectively analyzed 82 hospitalized children with adenovirus pneumonia, including 32 mild and 50 severe cases. Demographic, clinical, and laboratory variables were extracted from medical records. Laboratory variables were obtained from the first available blood tests within 24 hours after admission, whereas fever duration reflected the total febrile course. A surrogate Inflammasome-associated Inflammatory Injury Index (IAI) was calculated as the mean z-score of lactate dehydrogenase, C-reactive protein, aspartate aminotransferase, neutrophil-to-lymphocyte ratio, and maximal temperature. Logistic regression, support vector machine with radial basis function kernel, and random forest classifiers were evaluated using repeated stratified 5-fold cross-validation. SHAP values and unsupervised clustering were used for model interpretation and phenotype discovery. A small post-2019 cohort was used for exploratory single-center temporal validation. Results: Severe cases were younger and had longer fever duration, higher maximal temperature, lower hemoglobin, and higher alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase-MB levels than mild cases. IAI was significantly higher in severe disease. Random forest showed the best internal performance, with an AUC of 0.965 ± 0.031, PR-AUC of 0.980 ± 0.018, accuracy of 0.890, and F1-score of 0.913. Five-fold out-of-fold analysis yielded an AUC of 0.966 and a Brier score of 0.088. SHAP identified fever duration and IAI as the two leading contributors. Clustering identified an inflammatory injury-high phenotype comprising 11 patients, all with severe pneumonia. In exploratory temporal validation, the frozen random forest model achieved an AUC of 0.840 in 39 post-2019 cases. Conclusion: Routine clinical variables can support interpretable severity discrimination and phenotype discovery in pediatric adenovirus pneumonia. The inflammatory injury-high phenotype suggests a clinically detectable systemic inflammatory injury pattern biologically compatible with inflammasome-related inflammation. Because IAI is a surrogate clinical index rather than a direct molecular measure of inflammasome activation, prospective multicenter studies incorporating direct inflammasome biomarkers are required for biological validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.